Effect of Olaparib on Ovarian Cancer SKOV3 Cell Line Proliferation by Inhibiting the PI3K/AKT/mTOR Signaling Pathway
- Author:
Yan-Ying MA
1
Author Information
- Publication Type:Journal Article
- Keywords: Cell apoptosis; Dose dependent manner; Olaparib; PI3K/AKT/mTOR signaling pathway; Proliferation
- From: Chinese Pharmaceutical Journal 2019;54(1):36-41
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To analyze the involvement of PI3K/AKT/mTOR signaling pathway on the inhibiting the proliferation of ovarian cancer SKOV3 cell line by olaparib. METHODS: The SKOV3 cells were randomly divided into five groups: control group, olaparib low dose group (10 mg•L-1), olaparib medium dose group (30 mg•L-1), olaparib high dose group (90 mg•L-1), and PI3K protein inhibitor LY294002 group (10 mg•L-1). In addition to the control group, the rest of the cells were incubated with the corresponding doses of the compounds. DAPI and Western blotting were used to analyze the expression of apoptotic protein. qPCR, Western blotting and immunocytochemistry were adopted to detect the expression of PI3K/AKT/mTOR signaling pathway related proteins. RESULTS: After olaparib treatment, the proliferation of ovarian cancer SKOV3 cells was significantly inhibited (P<0.05). Apoptotic bodies in SKOV3 cells increased gradually, and the expression of caspase 3 and caspase 9 increased gradually (P<0.05), PI3K, AKT and mTOR expression gradually decreased (P<0.05) after olaparib medication. With the increase of olaparib level, the above effects were more obvious (P<0.05). CONCLUSION: Olaparib has an inhibitory effect on ovarian cancer SKOV3 cells, and it may play a role by inhibiting the PI3K/AKT/mTOR signaling pathway.
